LG Chem introduces new NASH drug candidate from China's TransThera

By Lim Chang-won Posted : August 18, 2020, 10:33 Updated : August 18, 2020, 10:33

[Courtesy of LG Chem]

SEOUL -- LG Chem, a chemical and battery wing of South Korea's LG Group, will accelerate the development of new non-alcoholic steatohepatitis (NASH) drugs through a deal to introduce a new drug candidate from TransThera Biosciences, a clinical-stage biotech company in China.

LG Chem said in a statement that the pre-clinical stage new NASH drug pipeline, TT-01025, of TransThera has global competitiveness considering effectiveness, safety, and clinical entry speed. NASH can be defined as the liver manifestation of a metabolic disorder and is the most severe form of non-alcoholic fatty liver disease closely related to the triple epidemic of obesity, pre-diabetes, and diabetes.

LG Chem said that it would secure global monopolistic development and sales right in the United States and Europe, excluding China and Japan. TransThera would receive up to $350 million in down payment and each milestone according to development and commercialization achievements.

LG Chem, which has a business division engaged in pharmaceutical products, said it would complete pre-clinical studies within this year and begin phase 1 clinical studies in the US in the first quarter of next year.

LG Chem Life Sciences head Son Jee-woong said that his company would develop new drugs that will have mutually supplementary treatment effects by procuring multiple new NASH pipelines with different action mechanisms. 

TT-01025 is featured by high selective effects on target proteins, TransThera CEO Frank Wu said, adding it is expected to show outstanding results in terms of safety.
기사 이미지 확대 보기